
Investment
Feds and OmniaBio partner to expand Hamilton facility for revolutionary cell and gene therapies
The Government of Canada announced a collaboration with OmniaBio to expand its facility at McMaster Innovation Park. This expansion will focus on manufacturing cell and gene therapies, providing production services globally, and strengthening Canada's role in global value chains. The project aims to revolutionize treatments for chronic diseases such as cancer, autoimmune conditions, diabetes, cardiovascular, and neurological diseases.
Apr 3, 2025

Investment
OmniaBio launches Canada’s largest cell and gene therapy manufacturing facility
New facility to drive biotech innovation with advanced AI and robotics, creating jobs and boosting local economy
Oct 17, 2024

Investment
McMaster-led study to revolutionize cancer care backed by $4.9M Pfizer investment
McMaster University leads groundbreaking study to transform multiple myeloma treatment
Jul 10, 2024

Investment
AstraZeneca’s $2.4B acquisition of Fusion Pharmaceuticals marks milestone in cancer treatment
McMaster University spin-out acquired by pharmaceutical giant for $2.4 billion